Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02216825Phase 2Completed

Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile

Role: lead

NCT01630668Phase 2Completed

Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule

Role: lead

NCT01185795Phase 2Completed

Efficacy of Cardioviva™ Probiotic Yogurt Formulation

Role: lead

NCT01341613Phase 2Completed

Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation

Role: lead

NCT01409668Phase 1Completed

Efficacy of Two Yogurt Formulations in Healthy Humans

Role: collaborator

All 5 trials loaded